Regeneron price target lowered to $1,045 from $1,059 at RBC Capital
RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,045 from $1,059 but keeps an Outperform rating on the shares. The ...
Regeneron price target lowered to $759 from $940 at Baird
Baird lowered the firm’s price target on Regeneron (REGN) to $759 from $940 and keeps a Neutral rating on the shares. The firms lower target ...
Regeneron's SWOT analysis: stock faces eylea challenges amid pipeline promise
Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...